Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The DNA Damage Response and Inflammation in Cancer
Vanessa Klapp, Beatriz Álvarez-Abril, Giuseppe Leuzzi, et al.
Cancer Discovery (2023) Vol. 13, Iss. 7, pp. 1521-1545
Open Access | Times Cited: 55

Showing 1-25 of 55 citing articles:

NK cells and solid tumors: therapeutic potential and persisting obstacles
Le Tong, Carlos Jiménez‐Cortegana, Apple H.M. Tay, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 96
Immunosurveillance in clinical cancer management
Guido Kroemer, Timothy A. Chan, Alexander M.M. Eggermont, et al.
CA A Cancer Journal for Clinicians (2023) Vol. 74, Iss. 2, pp. 187-202
Open Access | Times Cited: 62
The hallmarks of cancer immune evasion
Claudia Galassi, Timothy A. Chan, Ilio Vitale, et al.
Cancer Cell (2024) Vol. 42, Iss. 11, pp. 1825-1863
Closed Access | Times Cited: 57
Cancer cell metabolism and antitumour immunity
Mara De Martino, Jeffrey C. Rathmell, Lorenzo Galluzzi, et al.
Nature reviews. Immunology (2024) Vol. 24, Iss. 9, pp. 654-669
Open Access | Times Cited: 49
Type I interferon and cancer
Peter Holíček, Emma Guilbaud, Vanessa Klapp, et al.
Immunological Reviews (2023) Vol. 321, Iss. 1, pp. 115-127
Open Access | Times Cited: 43
SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion
Giuseppe Leuzzi, Alessandro Vasciaveo, Angelo Taglialatela, et al.
Cell (2024) Vol. 187, Iss. 4, pp. 861-881.e32
Open Access | Times Cited: 34
Immunogenicity of ferroptosis in cancer: a matter of context?
Elena Catanzaro, Robin Demuynck, Faye Naessens, et al.
Trends in cancer (2024) Vol. 10, Iss. 5, pp. 407-416
Closed Access | Times Cited: 16
Tumor-induced metabolic immunosuppression: Mechanisms and therapeutic targets
Jean‐Ehrland Ricci
Cell Reports (2025) Vol. 44, Iss. 1, pp. 115206-115206
Closed Access | Times Cited: 3
The Role of Chronic Inflammation in Pediatric Cancer
Christine Mella, Panogiotis Tsarouhas, Maximillian Brockwell, et al.
Cancers (2025) Vol. 17, Iss. 1, pp. 154-154
Open Access | Times Cited: 2
Epigenetic regulation of cancer
Lorenzo Galluzzi, Sheila Spada
International review of cell and molecular biology (2025), pp. xiii-xvii
Closed Access | Times Cited: 2
Inflammation in cancer: therapeutic opportunities from new insights
Yifei Xie, Fangfang Liu, Yunfei Wu, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Molecular determinants of immunogenic cell death elicited by radiation therapy
Claudia Galassi, Vanessa Klapp, Takahiro Yamazaki, et al.
Immunological Reviews (2023) Vol. 321, Iss. 1, pp. 20-32
Open Access | Times Cited: 19
Tumor-associated macrophages affect the treatment of lung cancer
Zhuchen Yu, Juntao Zou, Fei Xu
Heliyon (2024) Vol. 10, Iss. 7, pp. e29332-e29332
Open Access | Times Cited: 6
Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Tito A. Sandoval, Camilla Salvagno, Chang-Suk Chae, et al.
Cancer Discovery (2024) Vol. 14, Iss. 10, pp. 1901-1921
Open Access | Times Cited: 6
Exploring the gut microbiome’s role in colorectal cancer: diagnostic and prognostic implications
Guo-Ming Chen, Qing Ren, Zilan Zhong, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Advances in the mechanism of small nucleolar RNA and its role in DNA damage response
Liping Shen, Wencheng Zhang, Jia-Rong Deng, et al.
Military Medical Research (2024) Vol. 11, Iss. 1
Open Access | Times Cited: 5
Interleukin-1 receptor antagonist: An alternative therapy for cancer treatment
Fang Zhang, Jingting Jiang, Xiao Zheng
Life Sciences (2023) Vol. 335, pp. 122276-122276
Closed Access | Times Cited: 12
Radiopharmaceuticals as combinatorial partners for immune checkpoint inhibitors
Jean‐Pierre Pouget, Timothy A. Chan, Lorenzo Galluzzi, et al.
Trends in cancer (2023) Vol. 9, Iss. 11, pp. 968-981
Open Access | Times Cited: 11
The phosphorylation-deubiquitination positive feedback loop of the CHK2-USP7 axis stabilizes p53 under oxidative stress
Jingwei Liu, Liangzi Cao, Yubang Wang, et al.
Cell Reports (2024) Vol. 43, Iss. 6, pp. 114366-114366
Open Access | Times Cited: 4
Unraveling the underlying mechanisms of cancer stem cells in therapeutic resistance for optimizing treatment strategies
Yunhan Tan, Siyuan Qin, Zhe Zhang, et al.
MedComm – Oncology (2025) Vol. 4, Iss. 1
Open Access
Development and external validation of a model to predict recurrence in patients with non-muscle invasive bladder cancer
Jiajia Tang, L. Fan, Tianyu Huang, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
U2AF1 mutation causes an oxidative stress and DNA repair defect in hematopoietic and leukemic cells
Yishuang Li, Xuanjia Dong, Haiyan Xing, et al.
Free Radical Biology and Medicine (2025) Vol. 228, pp. 379-391
Closed Access
Anticancer Properties of Macroalgae: A Comprehensive Review
Sara Frazzini, Luciana Rossi
Marine Drugs (2025) Vol. 23, Iss. 2, pp. 70-70
Open Access
Identification of Immune Subtypes and a Prognostic Model for Lung Oligometastases in Cervical Cancer
Huijuan Yang, Congli Pu, Xuan Pei, et al.
(2025)
Closed Access
Role of PARP Inhibitors: A New Hope for Breast Cancer Therapy
K De, Malabendu Jana, Bhabadeb Chowdhury, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2773-2773
Open Access
Page 1 - Next Page

Scroll to top